# Acrivon Therapeutics Acrivon Therapeutics is an Asset Manager based in Watertown, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Watertown, United States - **Region:** North America - **Address:** Watertown, MA, United States - **Founded:** 2018 - **Assets under management:** Undisclosed - **Website:** acrivon.com - **LinkedIn:** https://www.linkedin.com/company/acrivon ## Regulatory record - **Reports private funds:** No ## About Acrivon Therapeutics is a company developing targeted therapies in oncology. It uses a proteomics-based platform for patient selection in oncology drug development. Acrivon's pipeline includes clinical-stage assets targeting DNA Damage Response and selective kinase inhibitors. ## Sectors - Oncology - Precision Medicine ## People - Peter Blume-Jensen — President & Chief Executive Officer - Erika G. P. Heiges — Chief Financial Officer & Treasurer ## Questions ### How does Acrivon's AP3 platform differ from standard genomic precision medicine? Acrivon's Predictive Precision Proteomics (AP3) platform directly measures drug-induced protein phosphorylation signaling in live tumor tissue, rather than inferring drug sensitivity from DNA mutations alone. The technology captures real-time functional responses of cancer pathways — a method Blume-Jensen and collaborators pioneered at Merck and Massachusetts General Hospital — and uses a machine-learning algorithm to predict patient response. This allows the firm to select patients for clinical trials based on a functional, dynamic biomarker rather than a static genetic one (per the firm's SEC filings). ### What is the clinical status of Acrivon's lead drug candidate? ACR-368, a CHK1/2 inhibitor, is in a registrational Phase 2b clinical trial for patients with platinum-resistant ovarian and endometrial cancer, with enrollment ongoing as of 2024. The trial is designed to support accelerated approval, and the company has guided for a partial clinical data readout in the second half of 2025. This single study is intended to serve as the basis for a New Drug Application filing, provided it meets its primary endpoint of objective response rate in the selected population (per clinicaltrials.gov). ### Does Acrivon have any revenue from approved products? No. Acrivon is a clinical-stage biotechnology company and does not generate revenue from commercial product sales. Its funding has come from venture capital — notably RA Capital and Perceptive Advisors — and a $120 million initial public offering in 2022. The firm's operational runway is dependent on equity capital markets and potential future partnership milestones, not recurring cash flow. ### What is the relationship between Acrivon's Watertown headquarters and its operations in Sweden? Acrivon was co-founded with roots at the Karolinska Institute in Stockholm, where some foundational work on the AP3 phosphoproteomics platform was developed. The company maintains a research laboratory and subsidiary in Sweden, which handles the high-throughput proteomics processing of patient tumor samples collected from its clinical trials. The US headquarters in Watertown houses executive leadership, clinical operations, and the translational science team. ### How large is Acrivon's drug pipeline beyond ACR-368? Acrivon's disclosed pipeline includes only two wholly owned programs: ACR-368, its CHK1/2 inhibitor, and ACR-2316, a WEE1 kinase inhibitor that entered clinical development in 2023 with a Phase 1 trial. The WEE1 program is designed to overcome the severe bone-marrow toxicity that has limited a competing drug from AstraZeneca, giving Acrivon a potential best-in-class window. The company's strategy is to build a pipeline of DNA damage repair inhibitors, with earlier-stage, undisclosed programs underpinned by the AP3 platform. ### Who are Acrivon's key scientific founders? The firm was founded by CEO Peter Blume-Jensen, who previously led oncology therapy-area research at Merck and held academic posts at Massachusetts General Hospital and Harvard Medical School. Co-founders include Professor Thomas Helleday of the Karolinska Institute, a DNA repair biology expert, and Professor Michael Yaffe of MIT and Beth Israel Deaconess Medical Center, a phosphoproteomics and systems biology specialist. This trio's combined expertise forms the company's foundational intellectual property. ## Related profiles - [VivoPower](https://altss.com/profile/vivopower-plc) - [Global Mofy AI](https://altss.com/profile/global-mofy-ai-ltd) --- Last updated: 2026-05-30T17:59:48.439Z Canonical page: https://altss.com/profile/acrivon-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology